{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T20:19:21Z","timestamp":1787170761440,"version":"build-2736575974"},"reference-count":134,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2019,6,3]],"date-time":"2019-06-03T00:00:00Z","timestamp":1559520000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,6,3]],"date-time":"2019-06-03T00:00:00Z","timestamp":1559520000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Biotechnol"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1038\/s41587-019-0137-8","type":"journal-article","created":{"date-parts":[[2019,6,3]],"date-time":"2019-06-03T12:19:05Z","timestamp":1559564345000},"page":"1425-1434","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":194,"title":["Gene editing for immune cell therapies"],"prefix":"10.1038","volume":"37","author":[{"given":"Stefanie R.","family":"Bailey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7578-0393","authenticated-orcid":false,"given":"Marcela V.","family":"Maus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,6,3]]},"reference":[{"key":"137_CR1","doi-asserted-by":"publisher","first-page":"4550","DOI":"10.1158\/1078-0432.CCR-11-0116","volume":"17","author":"SA Rosenberg","year":"2011","unstructured":"Rosenberg, S. A. et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin. Cancer Res. 17, 4550\u20134557 (2011).","journal-title":"Clin. Cancer Res."},{"key":"137_CR2","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1126\/science.1129003","volume":"314","author":"RA Morgan","year":"2006","unstructured":"Morgan, R. A. et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314, 126\u2013129 (2006).","journal-title":"Science"},{"key":"137_CR3","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1038\/mt.2010.272","volume":"19","author":"MR Parkhurst","year":"2011","unstructured":"Parkhurst, M. R. et al. T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis. Mol. Ther. 19, 620\u2013626 (2011).","journal-title":"Mol. Ther."},{"key":"137_CR4","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1038\/nm.3910","volume":"21","author":"AP Rapoport","year":"2015","unstructured":"Rapoport, A. P. et al. NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma. Nat. Med. 21, 914\u2013921 (2015).","journal-title":"Nat. Med."},{"key":"137_CR5","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1158\/2159-8290.CD-17-1417","volume":"8","author":"SP D\u2019Angelo","year":"2018","unstructured":"D\u2019Angelo, S. P. et al. Antitumor activity associated with prolonged persistence of adoptively transferred NY-ESO-1 c259T cells in synovial sarcoma. Cancer Discov. 8, 944\u2013957 (2018).","journal-title":"Cancer Discov."},{"key":"137_CR6","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1182\/blood-2009-03-211714","volume":"114","author":"LA Johnson","year":"2009","unstructured":"Johnson, L. A. et al. Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood 114, 535\u2013546 (2009).","journal-title":"Blood"},{"key":"137_CR7","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1126\/science.1251102","volume":"344","author":"E Tran","year":"2014","unstructured":"Tran, E. et al. Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer. Science 344, 641\u2013645 (2014).","journal-title":"Science"},{"key":"137_CR8","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1056\/NEJMoa1609279","volume":"375","author":"E Tran","year":"2016","unstructured":"Tran, E. et al. T-cell transfer therapy targeting mutant KRAS in cancer. N. Engl. J. Med. 375, 2255\u20132262 (2016).","journal-title":"N. Engl. J. Med."},{"key":"137_CR9","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1038\/s41591-018-0040-8","volume":"24","author":"N Zacharakis","year":"2018","unstructured":"Zacharakis, N. et al. Immune recognition of somatic mutations leading to complete durable regression in metastatic breast cancer. Nat. Med. 24, 724\u2013730 (2018).","journal-title":"Nat. Med."},{"key":"137_CR10","doi-asserted-by":"publisher","first-page":"2734","DOI":"10.1158\/1078-0432.CCR-15-2361","volume":"22","author":"M Leisegang","year":"2016","unstructured":"Leisegang, M. et al. Eradication of large solid tumors by gene therapy with a T-cell receptor targeting a single cancer-specific point mutation. Clin. Cancer Res. 22, 2734\u20132743 (2016).","journal-title":"Clin. Cancer Res."},{"key":"137_CR11","doi-asserted-by":"publisher","first-page":"5357","DOI":"10.1158\/1078-0432.CCR-18-0142","volume":"24","author":"T Matsuda","year":"2018","unstructured":"Matsuda, T. et al. Induction of neoantigen-specific cytotoxic T cells and construction of T-cell receptor-engineered T cells for ovarian cancer. Clin. Cancer Res. 24, 5357\u20135367 (2018).","journal-title":"Clin. Cancer Res."},{"key":"137_CR12","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1038\/nm.4051","volume":"22","author":"A Gros","year":"2016","unstructured":"Gros, A. et al. Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients. Nat. Med. 22, 433\u2013438 (2016).","journal-title":"Nat. Med."},{"key":"137_CR13","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1073\/pnas.90.2.720","volume":"90","author":"Z Eshhar","year":"1993","unstructured":"Eshhar, Z., Waks, T., Gross, G. & Schindler, D. G. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc. Natl Acad. Sci. USA 90, 720\u2013724 (1993).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"137_CR14","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1172\/JCI85309","volume":"126","author":"CJ Turtle","year":"2016","unstructured":"Turtle, C. J. et al. CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients. J. Clin. Invest. 126, 2123\u20132138 (2016).","journal-title":"J. Clin. Invest."},{"key":"137_CR15","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMoa1709866","volume":"378","author":"SL Maude","year":"2018","unstructured":"Maude, S. L. et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N. Engl. J. Med. 378, 439\u2013448 (2018).","journal-title":"N. Engl. J. Med."},{"key":"137_CR16","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa1804980","volume":"380","author":"SJ Schuster","year":"2019","unstructured":"Schuster, S. J. et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N. Engl. J. Med. 380, 45\u201356 (2019).","journal-title":"N. Engl. J. Med."},{"key":"137_CR17","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"SS Neelapu","year":"2017","unstructured":"Neelapu, S. S. et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N. Engl. J. Med. 377, 2531\u20132544 (2017).","journal-title":"N. Engl. J. Med."},{"key":"137_CR18","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","volume":"20","author":"FL Locke","year":"2019","unstructured":"Locke, F. L. et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1\u20132 trial. Lancet Oncol. 20, 31\u201342 (2019).","journal-title":"Lancet Oncol."},{"key":"137_CR19","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1182\/blood-2016-04-711903","volume":"128","author":"SA Ali","year":"2016","unstructured":"Ali, S. A. et al. T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma. Blood 128, 1688\u20131700 (2016).","journal-title":"Blood"},{"key":"137_CR20","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1016\/j.cell.2018.05.013","volume":"173","author":"MY Kim","year":"2018","unstructured":"Kim, M. Y. et al. Genetic inactivation of CD33 in hematopoietic stem cells to enable CAR T cell immunotherapy for acute myeloid leukemia. Cell 173, 1439\u20131453.e1419 (2018).","journal-title":"Cell"},{"key":"137_CR21","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1182\/blood-2017-01-761320","volume":"130","author":"D Gomes-Silva","year":"2017","unstructured":"Gomes-Silva, D. et al. CD7-edited T cells expressing a CD7-specific CAR for the therapy of T-cell malignancies. Blood 130, 285\u2013296 (2017).","journal-title":"Blood"},{"key":"137_CR22","doi-asserted-by":"publisher","first-page":"eaaa0984","DOI":"10.1126\/scitranslmed.aaa0984","volume":"9","author":"DM O\u2019Rourke","year":"2017","unstructured":"O\u2019Rourke, D. M. et al. A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma. Sci. Transl. Med. 9, eaaa0984 (2017).","journal-title":"Sci. Transl. Med."},{"key":"137_CR23","first-page":"1","volume":"3","author":"MV Maus","year":"2017","unstructured":"Maus, M. V. et al. An MHC-restricted antibody-based chimeric antigen receptor requires TCR-like affinity to maintain antigen specificity. Mol. Ther. Oncolytics 3, 1\u20139 (2017).","journal-title":"Mol. Ther. Oncolytics"},{"key":"137_CR24","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.ymthe.2017.10.002","volume":"26","author":"CE Brown","year":"2018","unstructured":"Brown, C. E. et al. Optimization of IL13R\u03b12-targeted chimeric antigen receptor T cells for improved anti-tumor efficacy against glioblastoma. Mol. Ther. 26, 31\u201344 (2018).","journal-title":"Mol. Ther."},{"key":"137_CR25","doi-asserted-by":"publisher","first-page":"3505","DOI":"10.1158\/0008-5472.CAN-15-0139","volume":"75","author":"HG Caruso","year":"2015","unstructured":"Caruso, H. G. et al. Tuning sensitivity of CAR to EGFR density limits recognition of normal tissue while maintaining potent antitumor activity. Cancer Res. 75, 3505\u20133518 (2015).","journal-title":"Cancer Res."},{"key":"137_CR26","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s40425-015-0099-4","volume":"3","author":"JA Hammill","year":"2015","unstructured":"Hammill, J. A. et al. Designed ankyrin repeat proteins are effective targeting elements for chimeric antigen receptors. J. Immunother. Cancer 3, 55 (2015).","journal-title":"J. Immunother. Cancer"},{"key":"137_CR27","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.1182\/blood.V128.22.2127.2127","volume":"128","author":"DL Hermanson","year":"2016","unstructured":"Hermanson, D. L. et al. A novel Bcma-specific, centyrin-based CAR-T product for the treatment of multiple myeloma. Blood 128, 2127 (2016).","journal-title":"Blood"},{"key":"137_CR28","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1158\/0008-5472.CAN-13-1365","volume":"74","author":"K Kudo","year":"2014","unstructured":"Kudo, K. et al. T lymphocytes expressing a CD16 signaling receptor exert antibody-dependent cancer cell killing. Cancer Res. 74, 93\u2013103 (2014).","journal-title":"Cancer Res."},{"key":"137_CR29","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.1158\/0008-5472.CAN-11-3890","volume":"72","author":"K Urbanska","year":"2012","unstructured":"Urbanska, K. et al. A universal strategy for adoptive immunotherapy of cancer through use of a novel T-cell antigen receptor. Cancer Res. 72, 1844\u20131852 (2012).","journal-title":"Cancer Res."},{"key":"137_CR30","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1016\/j.cell.2018.03.038","volume":"173","author":"JH Cho","year":"2018","unstructured":"Cho, J. H., Collins, J. J. & Wong, W. W. Universal chimeric antigen receptors for multiplexed and logical control of T cell responses. Cell 173, 1426\u20131438.e1411 (2018).","journal-title":"Cell"},{"key":"137_CR31","doi-asserted-by":"publisher","first-page":"215ra172","DOI":"10.1126\/scitranslmed.3006597","volume":"5","author":"VD Fedorov","year":"2013","unstructured":"Fedorov, V. D., Themeli, M. & Sadelain, M. PD-1- and CTLA-4-based inhibitory chimeric antigen receptors (iCARs) divert off-target immunotherapy responses. Sci. Transl. Med. 5, 215ra172 (2013).","journal-title":"Sci. Transl. Med."},{"key":"137_CR32","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1016\/j.cell.2016.01.011","volume":"164","author":"KT Roybal","year":"2016","unstructured":"Roybal, K. T. et al. Precision tumor recognition by T cells with combinatorial antigen-sensing circuits. Cell 164, 770\u2013779 (2016).","journal-title":"Cell"},{"key":"137_CR33","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.ccell.2019.02.003","volume":"35","author":"S Srivastava","year":"2019","unstructured":"Srivastava, S. et al. Logic-gated ROR1 chimeric antigen receptor expression rescues T cell-mediated toxicity to normal tissues and enables selective tumor targeting. Cancer Cell 35, 489\u2013503.e488 (2019).","journal-title":"Cancer Cell"},{"key":"137_CR34","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","volume":"371","author":"SL Maude","year":"2014","unstructured":"Maude, S. L. et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N. Engl. J. Med. 371, 1507\u20131517 (2014).","journal-title":"N. Engl. J. Med."},{"key":"137_CR35","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1158\/2159-8290.CD-18-0442","volume":"8","author":"RG Majzner","year":"2018","unstructured":"Majzner, R. G. & Mackall, C. L. Tumor antigen escape from CAR T-cell therapy. Cancer Discov. 8, 1219\u20131226 (2018).","journal-title":"Cancer Discov."},{"key":"137_CR36","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1158\/2159-8290.CD-15-1020","volume":"5","author":"E Sotillo","year":"2015","unstructured":"Sotillo, E. et al. Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy. Cancer Discov. 5, 1282\u20131295 (2015).","journal-title":"Cancer Discov."},{"key":"137_CR37","doi-asserted-by":"publisher","first-page":"2406","DOI":"10.1182\/blood-2015-08-665547","volume":"127","author":"R Gardner","year":"2016","unstructured":"Gardner, R. et al. Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy. Blood 127, 2406\u20132410 (2016).","journal-title":"Blood"},{"key":"137_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms12320","volume":"7","author":"E Jacoby","year":"2016","unstructured":"Jacoby, E. et al. CD19 CAR immune pressure induces B-precursor acute lymphoblastic leukaemia lineage switch exposing inherent leukaemic plasticity. Nat. Commun. 7, 12320 (2016).","journal-title":"Nat. Commun."},{"key":"137_CR39","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1038\/s41591-018-0146-z","volume":"24","author":"EJ Orlando","year":"2018","unstructured":"Orlando, E. J. et al. Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia. Nat. Med. 24, 1504\u20131506 (2018).","journal-title":"Nat. Med."},{"key":"137_CR40","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1182\/blood.V130.Suppl_1.846.846","volume":"130","author":"L Huang","year":"2017","unstructured":"Huang, L. et al. Sequential infusion of anti-CD22 and anti-CD19 chimeric antigen receptor T cells for adult patients with refractory\/relapsed B-cell acute lymphoblastic leukemia. Blood 130, 846 (2017).","journal-title":"Blood"},{"key":"137_CR41","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1093\/neuonc\/nox182","volume":"20","author":"K Bielamowicz","year":"2018","unstructured":"Bielamowicz, K. et al. Trivalent CAR T cells overcome interpatient antigenic variability in glioblastoma. Neuro-oncol. 20, 506\u2013518 (2018).","journal-title":"Neuro-oncol."},{"key":"137_CR42","doi-asserted-by":"publisher","first-page":"3036","DOI":"10.1172\/JCI83416","volume":"126","author":"M Hegde","year":"2016","unstructured":"Hegde, M. et al. Tandem CAR T cells targeting HER2 and IL13R\u03b12 mitigate tumor antigen escape. J. Clin. Invest. 126, 3036\u20133052 (2016).","journal-title":"J. Clin. Invest."},{"key":"137_CR43","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1182\/blood-2016-09-738245","volume":"129","author":"EA Chong","year":"2017","unstructured":"Chong, E. A. et al. PD-1 blockade modulates chimeric antigen receptor (CAR)-modified T cells: refueling the CAR. Blood 129, 1039\u20131041 (2017).","journal-title":"Blood"},{"key":"137_CR44","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","volume":"366","author":"SL Topalian","year":"2012","unstructured":"Topalian, S. L. et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366, 2443\u20132454 (2012).","journal-title":"N. Engl. J. Med."},{"key":"137_CR45","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1001\/jamaoncol.2016.1051","volume":"2","author":"CF Friedman","year":"2016","unstructured":"Friedman, C. F., Proverbs-Singh, T. A. & Postow, M. A. Treatment of the immune-related adverse effects of immune checkpoint inhibitors: a review. JAMA Oncol. 2, 1346\u20131353 (2016).","journal-title":"JAMA Oncol."},{"key":"137_CR46","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","volume":"366","author":"JR Brahmer","year":"2012","unstructured":"Brahmer, J. R. et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med. 366, 2455\u20132465 (2012).","journal-title":"N. Engl. J. Med."},{"key":"137_CR47","doi-asserted-by":"publisher","first-page":"34341","DOI":"10.18632\/oncotarget.9114","volume":"7","author":"ER Suarez","year":"2016","unstructured":"Suarez, E. R. et al. Chimeric antigen receptor T cells secreting anti-PD-L1 antibodies more effectively regress renal cell carcinoma in a humanized mouse model. Oncotarget 7, 34341\u201334355 (2016).","journal-title":"Oncotarget"},{"key":"137_CR48","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1038\/nbt.4195","volume":"36","author":"S Rafiq","year":"2018","unstructured":"Rafiq, S. et al. Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo. Nat. Biotechnol. 36, 847\u2013856 (2018).","journal-title":"Nat. Biotechnol."},{"key":"137_CR49","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.cell.2016.09.011","volume":"167","author":"KT Roybal","year":"2016","unstructured":"Roybal, K. T. et al. Engineering T cells with customized therapeutic response programs using synthetic Notch receptors. Cell 167, 419\u2013432 e416 (2016).","journal-title":"Cell"},{"key":"137_CR50","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1038\/mt.2014.47","volume":"22","author":"AM Leen","year":"2014","unstructured":"Leen, A. M. et al. Reversal of tumor immune inhibition using a chimeric cytokine receptor. Mol. Ther. 22, 1211\u20131220 (2014).","journal-title":"Mol. Ther."},{"key":"137_CR51","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1158\/0008-5472.CAN-15-2524","volume":"76","author":"X Liu","year":"2016","unstructured":"Liu, X. et al. A chimeric switch-receptor targeting PD1 augments the efficacy of second-generation CAR T cells in advanced solid tumors. Cancer Res. 76, 1578\u20131590 (2016).","journal-title":"Cancer Res."},{"key":"137_CR52","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-00462-8","volume":"7","author":"LJ Rupp","year":"2017","unstructured":"Rupp, L. J. et al. CRISPR\/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells. Sci. Rep. 7, 737 (2017).","journal-title":"Sci. Rep."},{"key":"137_CR53","doi-asserted-by":"publisher","first-page":"4133","DOI":"10.1182\/blood-2011-12-400044","volume":"119","author":"HJ Pegram","year":"2012","unstructured":"Pegram, H. J. et al. Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning. Blood 119, 4133\u20134141 (2012).","journal-title":"Blood"},{"key":"137_CR54","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.cell.2016.08.032","volume":"167","author":"M Boice","year":"2016","unstructured":"Boice, M. et al. Loss of the HVEM tumor suppressor in lymphoma and restoration by modified CAR-T cells. Cell 167, 405\u2013418.e413 (2016).","journal-title":"Cell"},{"key":"137_CR55","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1158\/2326-6066.CIR-17-0502","volume":"6","author":"N Siriwon","year":"2018","unstructured":"Siriwon, N. et al. CAR-T cells surface-engineered with drug-encapsulated nanoparticles can ameliorate intratumoral T-cell hypofunction. Cancer Immunol. Res. 6, 812\u2013824 (2018).","journal-title":"Cancer Immunol. Res."},{"key":"137_CR56","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1038\/nbt.4181","volume":"36","author":"L Tang","year":"2018","unstructured":"Tang, L. et al. Enhancing T cell therapy through TCR-signaling-responsive nanoparticle drug delivery. Nat. Biotechnol. 36, 707\u2013716 (2018).","journal-title":"Nat. Biotechnol."},{"key":"137_CR57","doi-asserted-by":"publisher","first-page":"177ra38","DOI":"10.1126\/scitranslmed.3005930","volume":"5","author":"RJ Brentjens","year":"2013","unstructured":"Brentjens, R. J. et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci. Transl. Med. 5, 177ra38 (2013).","journal-title":"Sci. Transl. Med."},{"key":"137_CR58","doi-asserted-by":"publisher","first-page":"2709","DOI":"10.1182\/blood-2011-10-384388","volume":"119","author":"JN Kochenderfer","year":"2012","unstructured":"Kochenderfer, J. N. et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood 119, 2709\u20132720 (2012).","journal-title":"Blood"},{"key":"137_CR59","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1056\/NEJMoa1103849","volume":"365","author":"DL Porter","year":"2011","unstructured":"Porter, D. L., Levine, B. L., Kalos, M., Bagg, A. & June, C. H. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N. Engl. J. Med. 365, 725\u2013733 (2011).","journal-title":"N. Engl. J. Med."},{"key":"137_CR60","doi-asserted-by":"publisher","first-page":"9385","DOI":"10.1158\/0008-5472.CAN-09-0494","volume":"69","author":"S Bobisse","year":"2009","unstructured":"Bobisse, S. et al. Reprogramming T lymphocytes for melanoma adoptive immunotherapy by T-cell receptor gene transfer with lentiviral vectors. Cancer Res. 69, 9385\u20139394 (2009).","journal-title":"Cancer Res."},{"key":"137_CR61","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1038\/s41375-018-0106-0","volume":"32","author":"MC Milone","year":"2018","unstructured":"Milone, M. C. & O\u2019Doherty, U. Clinical use of lentiviral vectors. Leukemia 32, 1529\u20131541 (2018).","journal-title":"Leukemia"},{"key":"137_CR62","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.ymthe.2017.09.008","volume":"26","author":"K Cornetta","year":"2018","unstructured":"Cornetta, K. et al. Absence of replication-competent lentivirus in the clinic: analysis of infused T cell products. Mol. Ther. 26, 280\u2013288 (2018).","journal-title":"Mol. Ther."},{"key":"137_CR63","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1038\/mt.2011.288","volume":"20","author":"AS Bear","year":"2012","unstructured":"Bear, A. S. et al. Replication-competent retroviruses in gene-modified T cells used in clinical trials: is it time to revise the testing requirements? Mol. Ther. 20, 246\u2013249 (2012).","journal-title":"Mol. Ther."},{"key":"137_CR64","doi-asserted-by":"publisher","first-page":"3363","DOI":"10.1172\/JCI86721","volume":"126","author":"P Kebriaei","year":"2016","unstructured":"Kebriaei, P. et al. Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cells. J. Clin. Invest. 126, 3363\u20133376 (2016).","journal-title":"J. Clin. Invest."},{"key":"137_CR65","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1038\/gt.2009.54","volume":"16","author":"PD Peng","year":"2009","unstructured":"Peng, P. D. et al. Efficient nonviral Sleeping Beauty transposon-based TCR gene transfer to peripheral blood lymphocytes confers antigen-specific antitumor reactivity. Gene Ther. 16, 1042\u20131049 (2009).","journal-title":"Gene Ther."},{"key":"137_CR66","doi-asserted-by":"publisher","first-page":"3132","DOI":"10.1172\/JCI35700","volume":"118","author":"S Hacein-Bey-Abina","year":"2008","unstructured":"Hacein-Bey-Abina, S. et al. Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J. Clin. Invest. 118, 3132\u20133142 (2008).","journal-title":"J. Clin. Invest."},{"key":"137_CR67","doi-asserted-by":"publisher","first-page":"132ra53","DOI":"10.1126\/scitranslmed.3003761","volume":"4","author":"J Scholler","year":"2012","unstructured":"Scholler, J. et al. Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells. Sci. Transl. Med. 4, 132ra53 (2012).","journal-title":"Sci. Transl. Med."},{"key":"137_CR68","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/s41586-018-0178-z","volume":"558","author":"JA Fraietta","year":"2018","unstructured":"Fraietta, J. A. et al. Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells. Nature 558, 307\u2013312 (2018).","journal-title":"Nature"},{"key":"137_CR69","doi-asserted-by":"publisher","first-page":"eaaj2013","DOI":"10.1126\/scitranslmed.aaj2013","volume":"9","author":"W Qasim","year":"2017","unstructured":"Qasim, W. et al. Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells. Sci. Transl. Med. 9, eaaj2013 (2017).","journal-title":"Sci. Transl. Med."},{"key":"137_CR70","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1016\/j.ymthe.2017.02.005","volume":"25","author":"DT MacLeod","year":"2017","unstructured":"MacLeod, D. T. et al. Integration of a CD19 CAR into the TCR alpha chain locus streamlines production of allogeneic gene-edited CAR T cells. Mol. Ther. 25, 949\u2013961 (2017).","journal-title":"Mol. Ther."},{"key":"137_CR71","first-page":"307ra156","volume":"7","author":"BD Sather","year":"2015","unstructured":"Sather, B. D. et al. Efficient modification of CCR5 in primary human hematopoietic cells using a megaTAL nuclease and AAV donor template. Sci. Transl. Med. 7, 307ra156 (2015).","journal-title":"Sci. Transl. Med."},{"key":"137_CR72","doi-asserted-by":"publisher","first-page":"e30","DOI":"10.1093\/nar\/gkv1121","volume":"44","author":"J Wang","year":"2016","unstructured":"Wang, J. et al. Highly efficient homology-driven genome editing in human T cells by combining zinc-finger nuclease mRNA and AAV6 donor delivery. Nucleic Acids Res. 44, e30 (2016).","journal-title":"Nucleic Acids Res."},{"key":"137_CR73","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/nature21405","volume":"543","author":"J Eyquem","year":"2017","unstructured":"Eyquem, J. et al. Targeting a CAR to the TRAC locus with CRISPR\/Cas9 enhances tumour rejection. Nature 543, 113\u2013117 (2017).","journal-title":"Nature"},{"key":"137_CR74","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/s41586-018-0326-5","volume":"559","author":"TL Roth","year":"2018","unstructured":"Roth, T. L. et al. Reprogramming human T cell function and specificity with non-viral genome targeting. Nature 559, 405\u2013409 (2018).","journal-title":"Nature"},{"key":"137_CR75","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1016\/j.jcyt.2016.05.005","volume":"18","author":"M Abou-El-Enein","year":"2016","unstructured":"Abou-El-Enein, M., Bauer, G., Medcalf, N., Volk, H. D. & Reinke, P. Putting a price tag on novel autologous cellular therapies. Cytotherapy 18, 1056\u20131061 (2016).","journal-title":"Cytotherapy"},{"key":"137_CR76","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1007\/s40259-017-0247-0","volume":"31","author":"M Ruella","year":"2017","unstructured":"Ruella, M. & Kenderian, S. S. Next-generation chimeric antigen receptor T-cell therapy: going off the shelf. BioDrugs 31, 473\u2013481 (2017).","journal-title":"BioDrugs"},{"key":"137_CR77","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.canlet.2016.07.001","volume":"380","author":"HR Mirzaei","year":"2016","unstructured":"Mirzaei, H. R., Mirzaei, H., Lee, S. Y., Hadjati, J. & Till, B. G. Prospects for chimeric antigen receptor (CAR) \u03b3\u03b4 T cells: a potential game changer for adoptive T cell cancer immunotherapy. Cancer Lett. 380, 413\u2013423 (2016).","journal-title":"Cancer Lett."},{"key":"137_CR78","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1038\/mt.2015.197","volume":"24","author":"MJ Osborn","year":"2016","unstructured":"Osborn, M. J. et al. Evaluation of TCR gene editing achieved by TALENs, CRISPR\/Cas9, and megaTAL nucleases. Mol. Ther. 24, 570\u2013581 (2016).","journal-title":"Mol. Ther."},{"key":"137_CR79","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1038\/nm.2700","volume":"18","author":"E Provasi","year":"2012","unstructured":"Provasi, E. et al. Editing T cell specificity towards leukemia by zinc finger nucleases and lentiviral gene transfer. Nat. Med. 18, 807\u2013815 (2012).","journal-title":"Nat. Med."},{"key":"137_CR80","doi-asserted-by":"publisher","first-page":"5697","DOI":"10.1182\/blood-2012-01-405365","volume":"119","author":"H Torikai","year":"2012","unstructured":"Torikai, H. et al. A foundation for universal T-cell based immunotherapy: T cells engineered to express a CD19-specific chimeric-antigen-receptor and eliminate expression of endogenous TCR. Blood 119, 5697\u20135705 (2012).","journal-title":"Blood"},{"key":"137_CR81","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1158\/1078-0432.CCR-16-1300","volume":"23","author":"J Ren","year":"2017","unstructured":"Ren, J. et al. Multiplex genome editing to generate universal CAR T cells resistant to PD1 inhibition. Clin. Cancer Res. 23, 2255\u20132266 (2017).","journal-title":"Clin. Cancer Res."},{"key":"137_CR82","doi-asserted-by":"publisher","first-page":"1970","DOI":"10.1038\/s41375-018-0065-5","volume":"32","author":"ML Cooper","year":"2018","unstructured":"Cooper, M. L. et al. An \u201coff-the-shelf\u201d fratricide-resistant CAR-T for the treatment of T cell hematologic malignancies. Leukemia 32, 1970\u20131983 (2018).","journal-title":"Leukemia"},{"key":"137_CR83","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.omtn.2017.10.005","volume":"9","author":"AS Gautron","year":"2017","unstructured":"Gautron, A. S. et al. Fine and predictable tuning of TALEN gene editing targeting for improved T cell adoptive immunotherapy. Mol. Ther. Nucleic Acids 9, 312\u2013321 (2017).","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"137_CR84","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1182\/blood-2013-03-478255","volume":"122","author":"H Torikai","year":"2013","unstructured":"Torikai, H. et al. Toward eliminating HLA class I expression to generate universal cells from allogeneic donors. Blood 122, 1341\u20131349 (2013).","journal-title":"Blood"},{"key":"137_CR85","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1038\/nbt.3860","volume":"35","author":"GG Gornalusse","year":"2017","unstructured":"Gornalusse, G. G. et al. HLA-E-expressing pluripotent stem cells escape allogeneic responses and lysis by NK cells. Nat. Biotechnol. 35, 765\u2013772 (2017).","journal-title":"Nat. Biotechnol."},{"key":"137_CR86","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1182\/blood-2018-99-111356","volume":"132","author":"R Benjamin","year":"2018","unstructured":"Benjamin, R. et al. Preliminary data on safety, cellular kinetics and anti-leukemic activity of UCART19, an allogeneic anti-CD19 CAR T-cell product, in a pool of adult and pediatric patients with high-risk CD19+ relapsed\/refractory B-cell acute lymphoblastic leukemia. Blood 132, 896 (2018).","journal-title":"Blood"},{"key":"137_CR87","doi-asserted-by":"publisher","first-page":"283","DOI":"10.3389\/fimmu.2018.00283","volume":"9","author":"RS Mehta","year":"2018","unstructured":"Mehta, R. S. & Rezvani, K. Chimeric antigen receptor expressing natural killer cells for the immunotherapy of cancer. Front. Immunol. 9, 283 (2018).","journal-title":"Front. Immunol."},{"key":"137_CR88","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1016\/j.leukres.2008.11.024","volume":"33","author":"L Boissel","year":"2009","unstructured":"Boissel, L., Betancur, M., Wels, W. S., Tuncer, H. & Klingemann, H. Transfection with mRNA for CD19 specific chimeric antigen receptor restores NK cell mediated killing of CLL cells. Leuk. Res. 33, 1255\u20131259 (2009).","journal-title":"Leuk. Res."},{"key":"137_CR89","doi-asserted-by":"publisher","first-page":"958","DOI":"10.3109\/10428194.2011.634048","volume":"53","author":"L Boissel","year":"2012","unstructured":"Boissel, L. et al. Comparison of mRNA and lentiviral based transfection of natural killer cells with chimeric antigen receptors recognizing lymphoid antigens. Leuk. Lymphoma 53, 958\u2013965 (2012).","journal-title":"Leuk. Lymphoma"},{"key":"137_CR90","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1016\/j.exphem.2006.06.001","volume":"34","author":"F Micucci","year":"2006","unstructured":"Micucci, F. et al. High-efficient lentiviral vector-mediated gene transfer into primary human NK cells. Exp. Hematol. 34, 1344\u20131352 (2006).","journal-title":"Exp. Hematol."},{"key":"137_CR91","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.molonc.2013.12.001","volume":"8","author":"H Jiang","year":"2014","unstructured":"Jiang, H. et al. Transfection of chimeric anti-CD138 gene enhances natural killer cell activation and killing of multiple myeloma cells. Mol. Oncol. 8, 297\u2013310 (2014).","journal-title":"Mol. Oncol."},{"key":"137_CR92","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1038\/leu.2013.279","volume":"28","author":"J Chu","year":"2014","unstructured":"Chu, J. et al. CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma. Leukemia 28, 917\u2013927 (2014).","journal-title":"Leukemia"},{"key":"137_CR93","doi-asserted-by":"publisher","first-page":"e1119354","DOI":"10.1080\/2162402X.2015.1119354","volume":"5","author":"S Gen\u00dfler","year":"2015","unstructured":"Gen\u00dfler, S. et al. Dual targeting of glioblastoma with chimeric antigen receptor-engineered natural killer cells overcomes heterogeneity of target antigen expression and enhances antitumor activity and survival. Oncoimmunology 5, e1119354 (2015).","journal-title":"Oncoimmunology"},{"key":"137_CR94","first-page":"6915912","volume":"2017","author":"Q Zhang","year":"2017","unstructured":"Zhang, Q. et al. Synergistic effects of cabozantinib and EGFR-specific CAR-NK-92 cells in renal cell carcinoma. J. Immunol. Res. 2017, 6915912 (2017).","journal-title":"J. Immunol. Res."},{"key":"137_CR95","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1038\/mt.2014.219","volume":"23","author":"K Sch\u00f6nfeld","year":"2015","unstructured":"Sch\u00f6nfeld, K. et al. Selective inhibition of tumor growth by clonal NK cells expressing an ErbB2\/HER2-specific chimeric antigen receptor. Mol. Ther. 23, 330\u2013338 (2015).","journal-title":"Mol. Ther."},{"key":"137_CR96","doi-asserted-by":"publisher","first-page":"17481","DOI":"10.1073\/pnas.0804788105","volume":"105","author":"A Kruschinski","year":"2008","unstructured":"Kruschinski, A. et al. Engineering antigen-specific primary human NK cells against HER-2 positive carcinomas. Proc. Natl Acad. Sci. USA 105, 17481\u201317486 (2008).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"137_CR97","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1182\/blood-2004-12-4797","volume":"106","author":"C Imai","year":"2005","unstructured":"Imai, C., Iwamoto, S. & Campana, D. Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells. Blood 106, 376\u2013383 (2005).","journal-title":"Blood"},{"key":"137_CR98","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1158\/2326-6066.CIR-14-0114","volume":"3","author":"Y Chu","year":"2015","unstructured":"Chu, Y. et al. Targeting CD20+ aggressive B-cell non-Hodgkin lymphoma by anti-CD20 CAR mRNA-modified expanded natural killer cells in vitro and in NSG mice. Cancer Immunol. Res. 3, 333\u2013344 (2015).","journal-title":"Cancer Immunol. Res."},{"key":"137_CR99","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1038\/leu.2017.226","volume":"32","author":"E Liu","year":"2018","unstructured":"Liu, E. et al. Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity. Leukemia 32, 520\u2013531 (2018).","journal-title":"Leukemia"},{"key":"137_CR100","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.1038\/leu.2017.8","volume":"31","author":"KH Chen","year":"2017","unstructured":"Chen, K. H. et al. Preclinical targeting of aggressive T-cell malignancies using anti-CD5 chimeric antigen receptor. Leukemia 31, 2151\u20132160 (2017).","journal-title":"Leukemia"},{"key":"137_CR101","doi-asserted-by":"publisher","first-page":"112783","DOI":"10.18632\/oncotarget.22626","volume":"8","author":"KG Pinz","year":"2017","unstructured":"Pinz, K. G. et al. Targeting T-cell malignancies using anti-CD4 CAR NK-92 cells. Oncotarget 8, 112783\u2013112796 (2017).","journal-title":"Oncotarget"},{"key":"137_CR102","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1089\/hum.2016.060","volume":"28","author":"KW Moyes","year":"2017","unstructured":"Moyes, K. W. et al. Genetically engineered macrophages: a potential platform for cancer immunotherapy. Hum. Gene Ther. 28, 200\u2013215 (2017).","journal-title":"Hum. Gene Ther."},{"key":"137_CR103","doi-asserted-by":"publisher","first-page":"12650","DOI":"10.1074\/jbc.M115.648220","volume":"290","author":"CC Ho","year":"2015","unstructured":"Ho, C. C. et al. \u201cVelcro\u201d engineering of high affinity CD47 ectodomain as signal regulatory protein \u03b1 (SIRP\u03b1) antagonists that enhance antibody-dependent cellular phagocytosis. J. Biol. Chem. 290, 12650\u201312663 (2015).","journal-title":"J. Biol. Chem."},{"key":"137_CR104","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1158\/0008-5472.CAN-12-2731","volume":"73","author":"JB Mitchem","year":"2013","unstructured":"Mitchem, J. B. et al. Targeting tumor-infiltrating macrophages decreases tumor-initiating cells, relieves immunosuppression, and improves chemotherapeutic responses. Cancer Res. 73, 1128\u20131141 (2013).","journal-title":"Cancer Res."},{"key":"137_CR105","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1021\/acs.bioconjchem.7b00768","volume":"29","author":"M Ray","year":"2018","unstructured":"Ray, M. et al. CRISPRed macrophages for cell-based cancer immunotherapy. Bioconjug. Chem. 29, 445\u2013450 (2018).","journal-title":"Bioconjug. Chem."},{"key":"137_CR106","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.stem.2012.12.006","volume":"12","author":"R Vizcardo","year":"2013","unstructured":"Vizcardo, R. et al. Regeneration of human tumor antigen-specific T cells from iPSCs derived from mature CD8+ T cells. Cell Stem Cell 12, 31\u201336 (2013).","journal-title":"Cell Stem Cell"},{"key":"137_CR107","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.stem.2012.11.002","volume":"12","author":"T Nishimura","year":"2013","unstructured":"Nishimura, T. et al. Generation of rejuvenated antigen-specific T cells by reprogramming to pluripotency and redifferentiation. Cell Stem Cell 12, 114\u2013126 (2013).","journal-title":"Cell Stem Cell"},{"key":"137_CR108","doi-asserted-by":"publisher","first-page":"3175","DOI":"10.1016\/j.celrep.2018.02.087","volume":"22","author":"R Vizcardo","year":"2018","unstructured":"Vizcardo, R. et al. Generation of tumor antigen-specific iPSC-derived thymic emigrants using a 3D thymic culture system. Cell Rep. 22, 3175\u20133190 (2018).","journal-title":"Cell Rep."},{"key":"137_CR109","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1038\/nbt.2678","volume":"31","author":"M Themeli","year":"2013","unstructured":"Themeli, M. et al. Generation of tumor-targeted human T lymphocytes from induced pluripotent stem cells for cancer therapy. Nat. Biotechnol. 31, 928\u2013933 (2013).","journal-title":"Nat. Biotechnol."},{"key":"137_CR110","doi-asserted-by":"publisher","first-page":"2425","DOI":"10.1158\/0008-5472.CAN-06-3977","volume":"67","author":"Y Zhao","year":"2007","unstructured":"Zhao, Y. et al. Extrathymic generation of tumor-specific T cells from genetically engineered human hematopoietic stem cells via Notch signaling. Cancer Res. 67, 2425\u20132429 (2007).","journal-title":"Cancer Res."},{"key":"137_CR111","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1038\/mt.2013.8","volume":"21","author":"F Giannoni","year":"2013","unstructured":"Giannoni, F. et al. Allelic exclusion and peripheral reconstitution by TCR transgenic T cells arising from transduced human hematopoietic stem\/progenitor cells. Mol. Ther. 21, 1044\u20131054 (2013).","journal-title":"Mol. Ther."},{"key":"137_CR112","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1111\/imr.12128","volume":"257","author":"E Gschweng","year":"2014","unstructured":"Gschweng, E., De Oliveira, S. & Kohn, D. B. Hematopoietic stem cells for cancer immunotherapy. Immunol. Rev. 257, 237\u2013249 (2014).","journal-title":"Immunol. Rev."},{"key":"137_CR113","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1038\/gt.2011.22","volume":"18","author":"S Senju","year":"2011","unstructured":"Senju, S. et al. Generation of dendritic cells and macrophages from human induced pluripotent stem cells aiming at cell therapy. Gene Ther. 18, 874\u2013883 (2011).","journal-title":"Gene Ther."},{"key":"137_CR114","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1038\/sj.cgt.7700826","volume":"12","author":"S Li","year":"2005","unstructured":"Li, S. et al. Bystander effect-mediated gene therapy of gliomas using genetically engineered neural stem cells. Cancer Gene Ther. 12, 600\u2013607 (2005).","journal-title":"Cancer Gene Ther."},{"key":"137_CR115","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.1002\/stem.1355","volume":"31","author":"J Martinez-Quintanilla","year":"2013","unstructured":"Martinez-Quintanilla, J. et al. Therapeutic efficacy and fate of bimodal engineered stem cells in malignant brain tumors. Stem Cells 31, 1706\u20131714 (2013).","journal-title":"Stem Cells"},{"key":"137_CR116","doi-asserted-by":"publisher","first-page":"12846","DOI":"10.1073\/pnas.97.23.12846","volume":"97","author":"KS Aboody","year":"2000","unstructured":"Aboody, K. S. et al. Neural stem cells display extensive tropism for pathology in adult brain: evidence from intracranial gliomas. Proc. Natl Acad. Sci. USA 97, 12846\u201312851 (2000).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"137_CR117","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1002\/ijc.28455","volume":"134","author":"C Altaner","year":"2014","unstructured":"Altaner, C. et al. Complete regression of glioblastoma by mesenchymal stem cells mediated prodrug gene therapy simulating clinical therapeutic scenario. Int. J. Cancer 134, 1458\u20131465 (2014).","journal-title":"Int. J. Cancer"},{"key":"137_CR118","doi-asserted-by":"publisher","first-page":"184ra59","DOI":"10.1126\/scitranslmed.3005365","volume":"5","author":"KS Aboody","year":"2013","unstructured":"Aboody, K. S. et al. Neural stem cell-mediated enzyme\/prodrug therapy for glioma: preclinical studies. Sci. Transl. Med. 5, 184ra59 (2013).","journal-title":"Sci. Transl. Med."},{"key":"137_CR119","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/nn.3019","volume":"15","author":"TM Kauer","year":"2011","unstructured":"Kauer, T. M., Figueiredo, J. L., Hingtgen, S. & Shah, K. Encapsulated therapeutic stem cells implanted in the tumor resection cavity induce cell death in gliomas. Nat. Neurosci. 15, 197\u2013204 (2011).","journal-title":"Nat. Neurosci."},{"key":"137_CR120","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s12307-010-0041-8","volume":"3","author":"X Ling","year":"2010","unstructured":"Ling, X. et al. Mesenchymal stem cells overexpressing IFN-\u03b2 inhibit breast cancer growth and metastases through Stat3 signaling in a syngeneic tumor model. Cancer Microenviron. 3, 83\u201395 (2010).","journal-title":"Cancer Microenviron."},{"key":"137_CR121","doi-asserted-by":"publisher","first-page":"655","DOI":"10.5966\/sctm.2013-0039","volume":"2","author":"AL Tobias","year":"2013","unstructured":"Tobias, A. L. et al. The timing of neural stem cell-based virotherapy is critical for optimal therapeutic efficacy when applied with radiation and chemotherapy for the treatment of glioblastoma. Stem Cells Transl. Med. 2, 655\u2013666 (2013).","journal-title":"Stem Cells Transl. Med."},{"key":"137_CR122","doi-asserted-by":"publisher","first-page":"dju090","DOI":"10.1093\/jnci\/dju090","volume":"106","author":"M Duebgen","year":"2014","unstructured":"Duebgen, M. et al. Stem cells loaded with multimechanistic oncolytic herpes simplex virus variants for brain tumor therapy. J. Natl Cancer Inst. 106, dju090 (2014).","journal-title":"J. Natl Cancer Inst."},{"key":"137_CR123","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1016\/j.jhep.2013.07.010","volume":"59","author":"HT Ong","year":"2013","unstructured":"Ong, H. T. et al. Systemically delivered measles virus-infected mesenchymal stem cells can evade host immunity to inhibit liver cancer growth. J. Hepatol. 59, 999\u20131006 (2013).","journal-title":"J. Hepatol."},{"key":"137_CR124","doi-asserted-by":"publisher","first-page":"12450","DOI":"10.1021\/nn505147w","volume":"8","author":"R Mooney","year":"2014","unstructured":"Mooney, R. et al. Neural stem cell-mediated intratumoral delivery of gold nanorods improves photothermal therapy. ACS Nano 8, 12450\u201312460 (2014).","journal-title":"ACS Nano"},{"key":"137_CR125","doi-asserted-by":"publisher","first-page":"8393","DOI":"10.1016\/j.biomaterials.2010.07.048","volume":"31","author":"M Roger","year":"2010","unstructured":"Roger, M. et al. Mesenchymal stem cells as cellular vehicles for delivery of nanoparticles to brain tumors. Biomaterials 31, 8393\u20138401 (2010).","journal-title":"Biomaterials"},{"key":"137_CR126","doi-asserted-by":"publisher","first-page":"378","DOI":"10.18632\/oncotarget.937","volume":"4","author":"B Auffinger","year":"2013","unstructured":"Auffinger, B. et al. Drug-loaded nanoparticle systems and adult stem cells: a potential marriage for the treatment of malignant glioma? Oncotarget 4, 378\u2013396 (2013).","journal-title":"Oncotarget"},{"key":"137_CR127","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1182\/blood-2014-04-566786","volume":"125","author":"YC Kim","year":"2015","unstructured":"Kim, Y. C. et al. Engineered antigen-specific human regulatory T cells: immunosuppression of FVIII-specific T- and B-cell responses. Blood 125, 1107\u20131115 (2015).","journal-title":"Blood"},{"key":"137_CR128","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1182\/blood-2016-07-727834","volume":"129","author":"J Yoon","year":"2017","unstructured":"Yoon, J. et al. FVIII-specific human chimeric antigen receptor T-regulatory cells suppress T- and B-cell responses to FVIII. Blood 129, 238\u2013245 (2017).","journal-title":"Blood"},{"key":"137_CR129","doi-asserted-by":"publisher","first-page":"126194","DOI":"10.1172\/jci.insight.126194","volume":"5","author":"AC Boroughs","year":"2019","unstructured":"Boroughs, A. C. et al. Chimeric antigen receptor costimulation domains modulate human regulatory T cell function. JCI Insight 5, 126194 (2019).","journal-title":"JCI Insight"},{"key":"137_CR130","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1126\/science.aaf6756","volume":"353","author":"CT Ellebrecht","year":"2016","unstructured":"Ellebrecht, C. T. et al. Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease. Science 353, 179\u2013184 (2016).","journal-title":"Science"},{"key":"137_CR131","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1182\/blood.V96.3.785.015k10_785_793","volume":"96","author":"RT Mitsuyasu","year":"2000","unstructured":"Mitsuyasu, R. T. et al. Prolonged survival and tissue trafficking following adoptive transfer of CD4zeta gene-modified autologous CD4+ and CD8+ T cells in human immunodeficiency virus-infected subjects. Blood 96, 785\u2013793 (2000).","journal-title":"Blood"},{"key":"137_CR132","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1056\/NEJMoa1300662","volume":"370","author":"P Tebas","year":"2014","unstructured":"Tebas, P. et al. Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV. N. Engl. J. Med. 370, 901\u2013910 (2014).","journal-title":"N. Engl. J. Med."},{"key":"137_CR133","doi-asserted-by":"publisher","first-page":"e1006753","DOI":"10.1371\/journal.ppat.1006753","volume":"13","author":"A Zhen","year":"2017","unstructured":"Zhen, A. et al. Long-term persistence and function of hematopoietic stem cell-derived chimeric antigen receptor T cells in a nonhuman primate model of HIV\/AIDS. PLoS Pathog. 13, e1006753 (2017).","journal-title":"PLoS Pathog."},{"key":"137_CR134","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1016\/j.ymthe.2016.12.023","volume":"25","author":"M Hale","year":"2017","unstructured":"Hale, M. et al. Engineering HIV-resistant, anti-HIV chimeric antigen receptor T cells. Mol. Ther. 25, 570\u2013579 (2017).","journal-title":"Mol. Ther."}],"container-title":["Nature Biotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41587-019-0137-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41587-019-0137-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41587-019-0137-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T03:33:50Z","timestamp":1659065630000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41587-019-0137-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,3]]},"references-count":134,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["137"],"URL":"https:\/\/doi.org\/10.1038\/s41587-019-0137-8","relation":{},"ISSN":["1087-0156","1546-1696"],"issn-type":[{"value":"1087-0156","type":"print"},{"value":"1546-1696","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,3]]},"assertion":[{"value":"26 August 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.V.M. is an inventor on patents in the field of CAR-T cell therapies; these patents are held either by University of Pennsylvania or by Massachusetts General Hospital\/Partners Healthcare.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}